Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara M Tolaney

Showing results (11-20 of 371) with videos related to

Pageof 38
Sort By:
Oncotarget|May 6, 2021
Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?Ilana Schlam, Sara M Tolaney
The New England Journal of Medicine|April 15, 2026
Sacituzumab Govitecan for Triple-Negative Breast Cancer. ReplySara M Tolaney, Peter Schmid
Journal of the Advanced Practitioner in Oncology|June 6, 2022
Immunotherapy for the Treatment of Triple-Negative Breast CancerSara M Tolaney, Lindsay Shaw
JCO Oncology Practice|May 19, 2023
Detecting and Managing T-DXd-Related Interstitial Lung Disease: The Five "S" RulesPaolo Tarantino, Sara M Tolaney
The New England Journal of Medicine|March 26, 2026
Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer. ReplyJavier Cortés, Sara M Tolaney
Cancer Research|October 17, 2022
The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid TumorsPaolo Tarantino, Sara M Tolaney
Clinical Advances in Hematology & Oncology : H&O|January 25, 2021
HER2-positive metastatic breast cancer: a comprehensive reviewPedro Exman, Sara M Tolaney
Therapeutic Advances in Medical Oncology|March 27, 2019
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistanceSonia Pernas, Sara M Tolaney
International Journal of Radiation Oncology, Biology, Physics|May 15, 2022
In Reply to Yilmaz et alJennifer R Bellon, Sara M Tolaney
Breast (Edinburgh, Scotland)|August 19, 2007
Follow-up care of patients with breast cancerSara M Tolaney, Eric P Winer
Pageof 38

Showing results (11-20 of 371) with videos related to

Sort By:
Pageof 38
Oncotarget|May 6, 2021
Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?Ilana Schlam, Sara M Tolaney
The New England Journal of Medicine|April 15, 2026
Sacituzumab Govitecan for Triple-Negative Breast Cancer. ReplySara M Tolaney, Peter Schmid
Journal of the Advanced Practitioner in Oncology|June 6, 2022
Immunotherapy for the Treatment of Triple-Negative Breast CancerSara M Tolaney, Lindsay Shaw
JCO Oncology Practice|May 19, 2023
Detecting and Managing T-DXd-Related Interstitial Lung Disease: The Five "S" RulesPaolo Tarantino, Sara M Tolaney
The New England Journal of Medicine|March 26, 2026
Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer. ReplyJavier Cortés, Sara M Tolaney
Cancer Research|October 17, 2022
The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid TumorsPaolo Tarantino, Sara M Tolaney
Clinical Advances in Hematology & Oncology : H&O|January 25, 2021
HER2-positive metastatic breast cancer: a comprehensive reviewPedro Exman, Sara M Tolaney
Therapeutic Advances in Medical Oncology|March 27, 2019
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistanceSonia Pernas, Sara M Tolaney
International Journal of Radiation Oncology, Biology, Physics|May 15, 2022
In Reply to Yilmaz et alJennifer R Bellon, Sara M Tolaney
Breast (Edinburgh, Scotland)|August 19, 2007
Follow-up care of patients with breast cancerSara M Tolaney, Eric P Winer
Pageof 38